However, with the recent approval of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib for the treatment of high-risk early-stage breast cancer, the therapeutic landscape is changing.13 Here, CDK4 is linked to breast carcinoma.